CA2205771A1 - Improved delivery of disease modifiers - Google Patents

Improved delivery of disease modifiers

Info

Publication number
CA2205771A1
CA2205771A1 CA002205771A CA2205771A CA2205771A1 CA 2205771 A1 CA2205771 A1 CA 2205771A1 CA 002205771 A CA002205771 A CA 002205771A CA 2205771 A CA2205771 A CA 2205771A CA 2205771 A1 CA2205771 A1 CA 2205771A1
Authority
CA
Canada
Prior art keywords
improved delivery
disease modifiers
disease
hyaluronan
modifiers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002205771A
Other languages
French (fr)
Other versions
CA2205771C (en
Inventor
Eva A. Turley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Priority to CA002205771A priority Critical patent/CA2205771C/en
Priority to AU73286/98A priority patent/AU740631B2/en
Priority to EP98920426A priority patent/EP0998297A2/en
Priority to JP54972998A priority patent/JP2001526666A/en
Priority to NZ501270A priority patent/NZ501270A/en
Priority to PCT/CA1998/000448 priority patent/WO1998052590A2/en
Publication of CA2205771A1 publication Critical patent/CA2205771A1/en
Application granted granted Critical
Publication of CA2205771C publication Critical patent/CA2205771C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition component comprising hyaluronan binding motif (HBM) interposed between a form of hyaluronan having a molecular weight (protein standard) less than 750,000 daltons and a disease modifier which comprises a peptide or protein.
CA002205771A 1997-05-22 1997-05-22 Improved delivery of disease modifiers Expired - Fee Related CA2205771C (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002205771A CA2205771C (en) 1997-05-22 1997-05-22 Improved delivery of disease modifiers
AU73286/98A AU740631B2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers
EP98920426A EP0998297A2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers
JP54972998A JP2001526666A (en) 1997-05-22 1998-05-11 Improved release of disease modulators
NZ501270A NZ501270A (en) 1997-05-22 1998-05-11 Pharmaceutical composition comprising hyaluronan (Mr less than 750,00) and a disease modifier (cytokine, a peptide mimicking a cytokine or a protein mimicking a cytokine) to enhance delivery of disease modifiers
PCT/CA1998/000448 WO1998052590A2 (en) 1997-05-22 1998-05-11 Improved delivery of disease modifiers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002205771A CA2205771C (en) 1997-05-22 1997-05-22 Improved delivery of disease modifiers

Publications (2)

Publication Number Publication Date
CA2205771A1 true CA2205771A1 (en) 1998-11-22
CA2205771C CA2205771C (en) 2002-05-14

Family

ID=4160694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205771A Expired - Fee Related CA2205771C (en) 1997-05-22 1997-05-22 Improved delivery of disease modifiers

Country Status (6)

Country Link
EP (1) EP0998297A2 (en)
JP (1) JP2001526666A (en)
AU (1) AU740631B2 (en)
CA (1) CA2205771C (en)
NZ (1) NZ501270A (en)
WO (1) WO1998052590A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
US20030082586A1 (en) 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
CA2406593A1 (en) * 2000-04-20 2001-11-01 Cangene Corporation Rhamm peptide conjugates
JP2007535486A (en) * 2003-05-07 2007-12-06 ラ ホーヤ インスティチュート フォー モレキュラー メディシン Method for promoting functional recovery of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid
DE102011122236A1 (en) * 2011-12-09 2013-06-13 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Composition useful e.g. in topical treatment of inflammatory diseases of skin and/or mucous membrane, comprises fusafungine and its derivate, and acidic glycosaminoglycan or its derivatives
FR3002452B1 (en) * 2013-02-28 2016-02-12 Dermaconcept Jmc TOPIC ANTIMICROBIAL DERMATOLOGICAL COMPOSITION
PE20181363A1 (en) 2015-09-23 2018-08-27 Genentech Inc OPTIMIZED VARIANTS OF ANTI-VEGF ANTIBODIES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
HUT76846A (en) * 1994-08-30 1997-12-29 Hyal Pharma Corp Hyaluronic acid and derivatives for modulation of cellular activity

Also Published As

Publication number Publication date
WO1998052590A3 (en) 1999-04-22
CA2205771C (en) 2002-05-14
AU740631B2 (en) 2001-11-08
EP0998297A2 (en) 2000-05-10
WO1998052590A2 (en) 1998-11-26
NZ501270A (en) 2001-08-31
AU7328698A (en) 1998-12-11
JP2001526666A (en) 2001-12-18

Similar Documents

Publication Publication Date Title
EP0809996A3 (en) Interferon conjugates
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
CA2333145A1 (en) Drug delivery system comprising a homeobox peptide and a non-peptide, non-nucleotide drug
HK1029124A1 (en) Lh-rh peptide analogues, their uses and pharmaceutical compositions containing them.
WO1997038689A3 (en) Enteric-coated pharmaceutical compositions of mycophenolate
EP1304346A3 (en) Conjugate of polyethylene glycol and chitosan
EP0875252A3 (en) Activated protein C formulations
CA2191088A1 (en) Copolymer-1 improvements in compositions of copolymers
AU1180997A (en) Novel taxoids, their preparation and pharmaceutical compositions containing them
HK1027957A1 (en) Pharmaceutical composition.
ZA974735B (en) Pharmaceutical compositions.
CA2223567A1 (en) Modified meningococcal polysaccharide conjugate vaccines
HK1047584A1 (en) Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process.
WO1999040112A8 (en) Neuroprotective peptides and uses thereof
CA2263181A1 (en) Anti-chlamydial methods and materials
HRP950612B1 (en) PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
EP0950708A3 (en) Enhanced affinity hyaluronan binding peptides
WO2002056833A3 (en) Preparation of a therapeutic composition
ZA989680B (en) Pharmaceutical composition.
CA2205771A1 (en) Improved delivery of disease modifiers
CA2191872A1 (en) Beta sheet forming peptides and gels made thereof
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
ZA971746B (en) Taxoids, their preparation and pharmaceutical compositions containing them.
HK1022853A1 (en) Pharmaceutical compositions.
CA2126241A1 (en) Sulphated polysaccharide, preparation thereof, pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed